|
|
IgA肾病的诊治进展
|
Abstract:
截至目前研究表明，免疫球蛋白A肾病(IgA nephropathy, IgAN)仍然是最常见的原发性肾小球肾炎，是慢性肾脏疾病的主要原因，或进展为终末期肾脏病。如今，肾活检仍被认定为诊断IgAN的“金标准”，表现为IgA肾小球沉积为主，通常伴有局部细胞增殖和基质扩张。目前IgAN发病机制尚不清晰，临床上应用的治疗方案尚未统一。本文主要就当前IgAN诊治与预后进行综述。
Immunoglobulin A nephropathy (IgAN) remains the most common primary glomerulonephritis and the leading cause of chronic kidney disease or progression to end-stage renal disease. Today, renal biopsy is still recognized as the “gold standard” for the diagnosis of IgAN, showing predominantly IgA glomerular deposition, often accompanied by local cell proliferation and stromal expansion. At present, the pathogenesis of IgAN is still unclear, and the clinical treatment has not been unified. This article mainly reviews the current diagnosis, treatment and prognosis of IgAN.
| [1] | Zhang, H. and Barratt, J. (2021) Is IgA Nephropathy the Same Disease in Different Parts of the World? Seminars in Immunopathology, 43, 707-715. https://doi.org/10.1007/s00281-021-00884-7 |
| [2] | Schena, F.P. and Nistor, I. (2018) Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 38, 435-442. https://doi.org/10.1016/j.semnephrol.2018.05.013 |
| [3] | Waldherr, R., Rambausek, M., Duncker, W.D. and Ritz, E. (1989) Frequency of Mesangial IgA Deposits in a Non-Selected Autopsy Series. Nephrology, Dialysis, Transplantation, 4, 943-946. https://doi.org/10.1093/ndt/4.11.943 |
| [4] | Rajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. https://doi.org/10.1016/j.amjms.2020.10.003 |
| [5] | Rovin, B., Adler, S., Barratt, J., Bridoux, F., Burdge, K., Chan, D., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779.
https://doi.org/10.1016/j.kint.2021.05.015 |
| [6] | Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 22, 1795-1803.
https://doi.org/10.1681/ASN.2011050464 |
| [7] | Trimarchi, H., Barratt, J., Cattran, D.C., et al. (2017) Oxford Clas-sification of IgA Nephropathy 2016: An Update from the IgA Nephropathy Classification Working Group. Kidney In-ternational, 91, 1014-1021.
https://doi.org/10.1016/j.kint.2017.02.003 |
| [8] | Prasad, N., Kumar, S., Manjunath, R., Bhadauria, D., et al. (2015) Real-Time Ultrasound-Guided Percutaneous Renal Biopsy with Needle Guide by Nephrologists Decreases Post-Biopsy Complications. Clinical Kidney Journal, 8, 151-156. https://doi.org/10.1093/ckj/sfv012 |
| [9] | 王雪, 刘亚, 孟巧云, 戴春. 血清IgA/C3值对IGA肾病的诊断价值[J]. 山东医药, 2021, 61(34): 83-86. |
| [10] | 黄勇, 黎才丽, 何玉叶. IgA/C3在IgA肾病中的诊断价值分析[J]. 国际检验医学杂志, 2018(1): 2290-2292. |
| [11] | 谢伟基, 洪桂填, 薛茜, 林智郡, 谢奕, 徐晓嫦, 等. 血清IgA/C3对IgA肾病诊断及治疗预后的意义[J]. 临床肾脏病杂志, 2019, 19(5): 311-316, 321. |
| [12] | Liu, L.L., Jiang, Y., Wang, L.N. and Liu, N. (2012) Urinary Mannose-Binding Lectin Is a Bi-omarker for Predicting the Progression of Immunoglobulin (Ig)A Nephropathy. Clinical and Experimental Immunology, 169, 148-155.
https://doi.org/10.1111/j.1365-2249.2012.04604.x |
| [13] | 张纪浩, 刘佳, 杨开月, 牛洪琳. IgA肾病无创诊断方法研究进展[J]. 中国中西医结合肾病杂志, 2021, 22(7): 650-652. |
| [14] | Hu, Q., Zhang, W.J., Lin, Z.Q., Wang, X.Y., Zheng, H.Y., Wei, H.M. and He, H.G. (2019) Combined Acoustic Radiation Force Impulse and Conventional Ultra-sound in the Quantitative Assessment of Immunoglobulin a Nephropathy. Ultrasound in Medicine & Biology, 45, 2309-2316. https://doi.org/10.1016/j.ultrasmedbio.2019.05.013 |
| [15] | Cheng, J., Zhang, X., Tian, J., Li, Q. and Chen, J. (2012) Combination Therapy an ACE Inhibitor and an Angiotensin Receptor Blocker for IgA Nephropathy: A Me-ta-Analysis. International Journal of Clinical Practice, 66, 917-923.
https://doi.org/10.1111/j.1742-1241.2012.02970.x |
| [16] | Ji, Y., Yang, K., Xiao, B., Lin, J., Zhao, Q., Bhuva, M.S. and Yang, H. (2019) Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blocker Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Journal of Cellular Biochemistry, 120, 3689-3695. https://doi.org/10.1002/jcb.27648 |
| [17] | Tian, L., Shao, X., Xie, Y., Wang, L., Wang, Q., Che, X., et al. (2015) The Long-Term Efficacy and Safety of Immunosuppressive Therapy on the Progression of IgA Nephropathy: A Meta-Analysis of Controlled Clinical Trials with More than 5-Year Follow-Up. Expert Opinion on Pharmacotherapy, 16, 1137-1147.
https://doi.org/10.1517/14656566.2015.1038238 |
| [18] | Gao, R., Wu, W., Wen, Y. and Li, X. (2017) Hydroxychlo-roquine Alleviates Persistent Proteinuria in IgA Nephropathy. International Urology and Nephrology, 49, 1233-1241. https://doi.org/10.1007/s11255-017-1574-2 |
| [19] | Fellstr？m, B.C., Barratt, J., Cook, H., Coppo, R., Feehally, J., et al. (2017) Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet (London, England), 389, 2117-2127. https://doi.org/10.1016/S0140-6736(17)30550-0 |
| [20] | 刘兴红, 戴欢子. IgA肾病精准治疗策略的探索[J]. 临床肾脏病杂志, 2022, 22(3): 253-258. |
| [21] | Yang, Y.Z., Chen, P., Liu, L.J., Cai, Q.Q., Shi, S.F., Chen, Y.Q., et al. (2019) Comparison of the Effects of Hydroxychloroquine and Corticosteroid Treatment on Proteinuria in IgA Nephropathy: A Case-Control Study. BMC Nephrology, 20, Article No. 297. https://doi.org/10.1186/s12882-019-1488-6 |
| [22] | Yang, Y.-Z., et al. (2019) Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22. https://doi.org/10.1053/j.ajkd.2019.01.026 |
| [23] | Xie, J., Lv, J., Wang, W., Li, G., Liu, Z., Chen, H., et al. (2018) Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Mul-ticenter Risk Assessment Study in Chinese Patients. American Journal of Kidney Diseases, 72, 371-380. https://doi.org/10.1053/j.ajkd.2018.01.043 |
| [24] | Barbour, S.J., Coppo, R., Zhang, H., Liu, Z.H., Suzuki, Y., et al. (2019) Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine, 179, 942-952. https://doi.org/10.1001/jamainternmed.2019.0600 |
